Streetbeat News

Revenues

ANGO

Four analysts have evaluated AngioDynamics (NASDAQ:ANGO) over the past three months, with a mix of bullish and bearish opinions. The average 12-month price target is $13.25, a 10.17% decline from the previous target. Analysts have adjusted their ratings and price targets in response to market conditions. AngioDynamics faces financial challenges, including a 22.06% revenue decline, but maintains strong net margins and effective debt management.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:02 pm

AMN

Analysts have provided mixed ratings for AMN Healthcare Services, with a recent average price target of $67.0, slightly up from $66.75. The company faces challenges with a -25.28% revenue decline but maintains strong net margins. Analysts' ratings reflect varied sentiments, with some raising and others lowering their price targets.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:01 pm

AMD

The article provides a comprehensive analysis of Advanced Micro Devices (AMD) in comparison to its competitors in the Semiconductors & Semiconductor Equipment industry. It highlights AMD's financial metrics, market position, and growth potential, noting its high P/E ratio, low P/B ratio, and strong revenue growth. Despite lower ROE, EBITDA, and gross profit, AMD's lower debt-to-equity ratio suggests a favorable financial position.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:00 pm

BMRN

Analysts have provided mixed ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) over the past three months, with a recent trend towards lowering price targets. The average 12-month price target has decreased by 5.06% to $102.33. Despite this, BioMarin shows strong financial performance with a 19.61% revenue growth rate and a net margin of 15.05%.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:00 pm

V

The article provides an in-depth analysis of Visa (NYSE:V) compared to its competitors in the Financial Services industry. Visa shows a lower P/E ratio than the industry average, indicating potential undervaluation. However, its high P/B and P/S ratios suggest it might be overvalued based on book value and sales. Visa's ROE, EBITDA, and gross profit are significantly higher than the industry average, indicating strong profitability and operational efficiency. Despite these strengths, Visa's revenue growth is below the industry average, which could be a concern for future performance.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:00 pm

LLY

Eli Lilly (NYSE:LLY) is evaluated against its peers in the Pharmaceuticals industry. The company shows high valuation metrics (PE, PB, PS ratios) compared to industry averages, indicating potential overvaluation. However, it has strong ROE and revenue growth, suggesting profitability and future prospects. Concerns arise from lower EBITDA and gross profit, indicating potential operational inefficiencies.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:00 pm

TW

Tradeweb Markets shares are experiencing an uptick following the announcement of a year-over-year increase in average daily volume for September and Q3.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:56 pm

STLA

Stellantis, the parent company of Jeep and Ram, is implementing strict cost-cutting measures to conserve cash and reverse declining profits. The company's CFO has revived the 'doghouse' approach to limit external spending.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:50 pm

SNY

Sanofi has sold the global rights to its rare autoimmune drug Enjaymo to Recordati for $825 million upfront, with potential milestone payments of $250 million. Enjaymo, approved by the FDA in 2022, is expected to see significant revenue growth. The deal is set to close by the end of 2024.

Portfolio Pulse from Vandana Singh

October 04, 2024 | 2:42 pm

TMUS

VZ

BakedBot AI, founded by Martez Knox, is revolutionizing the cannabis industry with AI-driven bots that enhance customer experiences and streamline dispensary operations. The company addresses marketing challenges by using AI to improve customer engagement and optimize business processes. BakedBot AI's tools help dispensaries personalize customer interactions, optimize pricing, and manage inventory effectively.

Portfolio Pulse from Nicolás Jose Rodriguez

October 04, 2024 | 2:27 pm